Iovance Biotherapeutics has increased its 2026 revenue guidance to $410–$420 million due to faster adoption of its cancer treatment Amtagvi, supported by expanding access, greater physician awareness, and improved manufacturing speed. The company’s ongoing trials in melanoma and lung cancer, along with plans for international expansion, could significantly increase Amtagvi’s market potential beyond the current $1 billion peak sales estimate. Internal manufacturing improvements are expected to raise gross margins to 65–70%, although risks remain from continued cash burn and possible stock dilution. Despite a strong stock performance this year, investors should watch for clinical or regulatory setbacks that could impact future growth.
Iovance Biotherapeutics is the subject of this update. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 05, 2026 16:21 WIB: Out of 100 priced health-sector US stocks, 37 rose and 39 fell today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.34, down 1.87%, Inovio Pharmaceuticals Inc (INO) at USD 1.18, up 1.72%, and Citius Pharmaceuticals Inc (CTXR) at USD 0.54, up 1.58%.
Rapid Dose Therapeutics announced it will issue common shares to settle $142,067.63 of accrued interest on its secured convertible notes by October 15, 2026. The notes, originally issued in 2023, bear 18% annual interest payable quarterly in shares a...
JP Morgan has put Unilever on positive watch and Haleon on negative watch ahead of the third-quarter earnings reports from European consumer staples companies. The broker also favors Givaudan, Heineken, and Danone, particularly in beer, ingredients, ...
Intel shares fell 4% after Elon Musk confirmed discussions with Taiwan Semiconductor Manufacturing (TSMC) about joining Terafab, a Texas chip venture where Intel is currently the sole manufacturing partner. This potential partnership could reduce Int...
Micron's stock short volume ratio surged to 55.34 on October 2, marking a two-week high and signaling more bearish bets than bullish for the first time in that period. This rise coincides with market volatility following Micron's September 30 earning...
Omai Gold Mines Corp. has filed a National Instrument 43-101 Technical Report supporting its Preliminary Economic Assessment for the Wenot Open Pit and Gilt Underground deposits in Guyana. The report projects an average annual gold production of appr...
